Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Biomodulators" patented technology

Polyether-ether-ketone composite material with enhanced 3D printing function and preparation method of polyether-ether-ketone composite material

The invention relates to the technical field of biological materials for 3D printing, in particular to a polyether-ether-ketone composite material with an enhanced 3D printing function and a preparation method of the polyether-ether-ketone composite material. The invention discloses a polyether-ether-ketone composite material with an enhanced 3D printing function. The material is prepared from the following raw materials in parts by mass: 75-85 parts of polyether-ether-ketone, 5-10 parts of a modified bioactive material, 1-3 parts of carbon nanotubes, 0.5-2 parts of an organic nucleating agent, 0.1-1 part of a biological regulator and 0.1-1 part of an antibacterial agent, the modified bioactive material is modified hydroxyapatite and / or modified tricalcium phosphate. According to the basic formula, the synergistic effect of multifunctional components is achieved, the defects of an existing PEEK material in the aspects of biological activity and crystallization performance are overcome through the components such as polyether-ether-ketone, the modified bioactive material and the carbon nanotubes which are meticulously proportioned, and excellent mechanical performance and biocompatibility are provided.
Owner:ZHEJIANG ZHONGJU BIOTECHNOLOGY CO LTD

Hydroxyphenyl-indoline-2-one cancer therapeutics

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

Multi-sensor array for customizing photobiomodulation dosing

A sensor array for monitoring and customizing photobiologically modulated doses is disclosed. The sensor array includes a temperature sensor for monitoring the surface temperature at the target treatment site when photons are emitted from a photobiologically modulated device onto the target treatment site.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

Steroid derivative regulators, method for preparing the same, and uses thereof

The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator the of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases, wherein the substituents of the formula (I) are as defined in the description.
Owner:JIANGSU HANSOH PHARMA CO LTD +1

Steroid derivative modulators, their manufacturing methods and applications

To provide steroid derivative modulators, a method for preparing the same, and uses thereof.SOLUTION: The invention relates to steroid derivative modulators, a method for preparing the same, and uses thereof. In particular, the invention relates to a compound represented by the general formula (I), a method for preparing the same, a pharmaceutical composition containing the compound, and applications thereof as a GABAA receptor modulator in treating depression, convulsion, Parkinson's disease, and nervous system diseases, where the substituents in the general formula (I) are the same as defined in the specification.SELECTED DRAWING: None
Owner:JIANGSU HANSOH PHARMA CO LTD +1

Method for delivering plant-derived biomodulators based on nanocarriers

The invention discloses a nano-carrier-based plant-derived biological regulator delivery method, and particularly relates to the technical field of nano-material application, and the method comprises the following steps: constructing a locked risk map based on soil mineral distribution, carrying out responsive structure modification on a high-adsorption area nano-carrier, and regulating and controlling the release rhythm of the nano-carrier; in combination with release history and soil microenvironment characteristics, the nano-carrier structure is subjected to multi-level regulation and control, and a release path is dynamically adjusted; in the application process, rhizosphere distribution and plant response data are collected through the nanoprobe, a next-round delivery strategy is modeled and optimized, and closed-loop accurate delivery of the plant-source biological regulator is achieved; according to the method, high-adsorption area identification before application is achieved through soil mineral map construction, the release rhythm is controlled by adopting a response type nano-carrier structure, the release path and dosage are dynamically adjusted in combination with data collected by a rhizosphere probe, multi-period, regionalized and closed-loop regulator delivery is achieved, and application accuracy and environmental adaptability are improved.
Owner:ZHEJIANG UNIV OF SCI & TECH